サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1349443

抗感染症薬市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年から2031年

Anti-Infective Drugs Market (Drug Class: Antibacterials, Antivirals, Antifungals, and Others; and Route of Administration: Oral, Parenteral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 190 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗感染症薬市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年から2031年
出版日: 2023年07月31日
発行: Transparency Market Research
ページ情報: 英文 190 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗感染症薬市場- レポートの範囲

世界の抗感染症薬市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、2023年を基準年、2031年を予測年とし、2017年から2031年までの世界市場の収益を提供します。また、2023年から2031年までの世界市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、抗感染症薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

市場スナップショット
2023年の市場価値 1,391億米ドル
2031年の市場価値 1,779億米ドル
CAGR4%

このレポートは、世界の抗感染症薬市場の競合情勢を詳しく調査しています。世界の抗感染症薬市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界の抗感染症薬市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年

第5章 重要な洞察

  • 主要国の世界の病気の有病率と罹患率
  • 規制シナリオ：地域別
  • 地域/世界ごとの償還シナリオ
  • パイプライン分析
  • 主要製品/ブランド分析
  • 主な合併と買収
  • COVID-19感染症パンデミックによる業界への影響（バリューチェーンと短期・中期・長期的な影響）

第6章 世界市場の分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：薬剤クラス別、2017-2031
    • 抗菌剤
      • B-ラクタム
      • キノロン類
      • マクロライド系
      • テトラサイクリン
      • アミノグリコシド
      • その他
    • 抗ウイルス薬
      • その他の抗ウイルス薬
      • アダマンタン系抗ウイルス薬
      • 抗ウイルスブースター
      • その他
    • 抗真菌薬
      • アゾール
      • エキノカンジン
      • ポリエン
      • その他
    • その他
  • 市場魅力分析：薬剤クラス別

第7章 世界市場の分析と予測：投与経路別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：投与経路別、2017-2031
    • 経口
    • 非経口
    • その他
  • 市場魅力度分析：投与経路別

第8章 世界市場の分析と予測：適応症別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：適応症別、2017-2031
    • 肺炎
    • 敗血症
    • 結核
    • インフルエンザ
    • HIV感染症
    • 肝炎ウイルス感染症
    • 呼吸器ウイルス感染症
    • その他
  • 市場魅力度分析：適応症別

第9章 世界市場の分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な発見/開発
  • 市場金額予測：流通チャネル別、2017-2031
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力度分析：流通チャネル別

第10章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017-2031
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 国・地域別の市場魅力度

第11章 北米市場の分析と予測

第12章 欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東およびアフリカ市場の分析と予測

第16章 競合情勢

  • 市場プレーヤー-競合マトリックス（企業の階層および規模別）
  • 市場シェア分析：企業別、2022年
  • 企業プロファイル
    • Pfizer Inc.
    • Gland Pharma Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • GlaxoSmithKline plc
    • Gilead Sciences, Inc.
    • Merck &Co., Inc.
    • Abbott
    • Astellas Pharma Inc.
    • Alkem Laboratories
    • AstraZeneca
    • Eli Lilly and Company
    • Johnson &Johnson Services, Inc.
    • Takeda Pharmaceutical Company Limited
    • Sanofi
図表

List of Tables

  • Table 01: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 03: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 04: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 05: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 06: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 07: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 08: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 09: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 10: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 11: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 12: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 13: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 14: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 16: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 17: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 18: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 19: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 20: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 21: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 22: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 23: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 24: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 25: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 26: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 27: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 28: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 29: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 30: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 31: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 32: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 33: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 34: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 35: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 36: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 37: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 38: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 39: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 40: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 41: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 42: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antibacterials, 2017-2031
  • Table 43: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antivirals, 2017-2031
  • Table 44: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Antifungals, 2017-2031
  • Table 45: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 46: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 47: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 48: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 03: Global Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 04: Global Anti-infective Drugs Market Revenue (US$ Mn), by Antibacterials, 2017-2031
  • Figure 05: Global Anti-infective Drugs Market Revenue (US$ Mn), by Antivirals, 2017-2031
  • Figure 06: Global Anti-infective Drugs Market Revenue (US$ Mn), by Antifungals, 2017-2031
  • Figure 07: Global Anti-infective Drugs Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 08: Global Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 09: Global Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 10: Global Anti-infective Drugs Market Revenue (US$ Mn), by Oral, 2017-2031
  • Figure 11: Global Anti-infective Drugs Market Revenue (US$ Mn), by Parenteral, 2017-2031
  • Figure 12: Global Anti-infective Drugs Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 13: Global Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 14: Global Anti-infective Drugs Market Revenue (US$ Mn), by Pneumonia, 2017-2031
  • Figure 15: Global Anti-infective Drugs Market Revenue (US$ Mn), by Sepsis, 2017-2031
  • Figure 16: Global Anti-infective Drugs Market Revenue (US$ Mn), by Tuberculosis, 2017-2031
  • Figure 17: Global Anti-infective Drugs Market Revenue (US$ Mn), by Influenza, 2017-2031
  • Figure 18: Global Anti-infective Drugs Market Revenue (US$ Mn), by HIV Infection, 2017-2031
  • Figure 19: Global Anti-infective Drugs Market Revenue (US$ Mn), by Hepatitis Virus Infection, 2017-2031
  • Figure 20: Global Anti-infective Drugs Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 21: Global Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 22: Global Anti-infective Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 23: Global Anti-infective Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 24: Global Anti-infective Drugs Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 25: Global Anti-infective Drugs Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 26: Global Anti-infective Drugs Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 27: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 28: North America Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 29: North America Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 30: North America Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 31: North America Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 32: North America Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 33: North America Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 34: North America Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 35: North America Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 36: North America Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 37: North America Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 38: North America Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 39: Europe Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 40: Europe Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 41: Europe Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 42: Europe Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 43: Europe Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 44: Europe Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 45: Europe Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 46: Europe Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 47: Europe Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 48: Europe Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 49: Europe Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 51: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 52: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 53: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 54: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 55: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 56: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 57: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 58: Asia Pacific Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 59: Asia Pacific Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 60: Asia Pacific Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Latin America Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 62: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 63: Latin America Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 64: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 65: Latin America Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 66: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 67: Latin America Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 68: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 69: Latin America Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 70: Latin America Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 71: Latin America Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 72: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
  • Figure 73: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 74: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Route of Administration, 2022 and 2031
  • Figure 75: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Route of Administration, 2022-2031
  • Figure 76: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 77: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 78: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 79: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 80: Middle East & Africa Anti-infective Drugs Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 81: Middle East & Africa Anti-infective Drugs Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 82: Middle East & Africa Anti-infective Drugs Market Value (US$ Mn) Forecast, 2017-2031
目次
Product Code: TMRGL41204

Anti-Infective Drugs Market - Scope of Report

TMR's report on the global anti-infective drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global anti-infective drugs market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anti-infective drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the anti-infective drugs market.

Market Snapshot
Market Value in 2023US$ 139.1 Bn
Market Value in 2031US$ 177.9 Bn
CAGR4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anti-infective drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anti-infective drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anti-infective drugs market.

The report delves into the competitive landscape of the global anti-infective drugs market. Key players operating in the global anti-infective drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anti-infective drugs market profiled in this report.

Key Questions Answered in Global Anti-Infective Drugs Market Report:

  • What is the sales/revenue generated by anti-infective drugs across all regions during the forecast period?
  • What are the opportunities in the global anti-infective drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Anti-Infective Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global anti-infective drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global anti-infective drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anti-infective drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Anti-infective Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Anti-infective Drugs Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Disease Prevalence & Incidence Rate Globally With Key Countries
  • 5.2. Regulatory Scenario, by Region
  • 5.3. Reimbursement Scenario by Region/Globally
  • 5.4. Pipeline Analysis
  • 5.5. Key Product/Brand Analysis
  • 5.6. Key Mergers & Acquisitions
  • 5.7. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term Impact)

6. Global Anti-infective Drugs Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Antibacterials
      • 6.3.1.1. B-lactams
      • 6.3.1.2. Quinolones
      • 6.3.1.3. Macrolides
      • 6.3.1.4. Tetracycline
      • 6.3.1.5. Aminoglycoside
      • 6.3.1.6. Others
    • 6.3.2. Antivirals
      • 6.3.2.1. Miscellaneous Antivirals
      • 6.3.2.2. Adamantane Antivirals
      • 6.3.2.3. Antiviral Boosters
      • 6.3.2.4. Others
    • 6.3.3. Antifungals
      • 6.3.3.1. Azoles
      • 6.3.3.2. Echinocandins
      • 6.3.3.3. Polyenes
      • 6.3.3.4. Others
    • 6.3.4. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Anti-infective Drugs Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Anti-infective Drugs Market Analysis and Forecast, by Indication

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Indication, 2017-2031
    • 8.3.1. Pneumonia
    • 8.3.2. Sepsis
    • 8.3.3. Tuberculosis
    • 8.3.4. Influenza
    • 8.3.5. HIV Infection
    • 8.3.6. Hepatitis Virus Infection
    • 8.3.7. Respiratory Virus Infection
    • 8.3.8. Others
  • 8.4. Market Attractiveness Analysis, by Indication

9. Global Anti-infective Drugs Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Anti-infective Drugs Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2017-2031
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Country/Region

11. North America Anti-infective Drugs Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Antibacterials
      • 11.2.1.1. B-lactams
      • 11.2.1.2. Quinolones
      • 11.2.1.3. Macrolides
      • 11.2.1.4. Tetracycline
      • 11.2.1.5. Aminoglycoside
      • 11.2.1.6. Others
    • 11.2.2. Antivirals
      • 11.2.2.1. Miscellaneous Antivirals
      • 11.2.2.2. Adamantane Antivirals
      • 11.2.2.3. Antiviral Boosters
      • 11.2.2.4. Others
    • 11.2.3. Antifungals
      • 11.2.3.1. Azoles
      • 11.2.3.2. Echinocandins
      • 11.2.3.3. Polyenes
      • 11.2.3.4. Others
    • 11.2.4. Others
  • 11.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.3.1. Oral
    • 11.3.2. Parenteral
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Indication, 2017-2031
    • 11.4.1. Pneumonia
    • 11.4.2. Sepsis
    • 11.4.3. Tuberculosis
    • 11.4.4. Influenza
    • 11.4.5. HIV Infection
    • 11.4.6. Hepatitis Virus Infection
    • 11.4.7. Respiratory Virus Infection
    • 11.4.8. Others
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Class
    • 11.7.2. By Route of Administration
    • 11.7.3. By Indication
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country/Sub-region

12. Europe Anti-infective Drugs Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Antibacterials
      • 12.2.1.1. B-lactams
      • 12.2.1.2. Quinolones
      • 12.2.1.3. Macrolides
      • 12.2.1.4. Tetracycline
      • 12.2.1.5. Aminoglycoside
      • 12.2.1.6. Others
    • 12.2.2. Antivirals
      • 12.2.2.1. Miscellaneous Antivirals
      • 12.2.2.2. Adamantane Antivirals
      • 12.2.2.3. Antiviral Boosters
      • 12.2.2.4. Others
    • 12.2.3. Antifungals
      • 12.2.3.1. Azoles
      • 12.2.3.2. Echinocandins
      • 12.2.3.3. Polyenes
      • 12.2.3.4. Others
    • 12.2.4. Others
  • 12.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.3.1. Oral
    • 12.3.2. Parenteral
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Indication, 2017-2031
    • 12.4.1. Pneumonia
    • 12.4.2. Sepsis
    • 12.4.3. Tuberculosis
    • 12.4.4. Influenza
    • 12.4.5. HIV Infection
    • 12.4.6. Hepatitis Virus Infection
    • 12.4.7. Respiratory Virus Infection
    • 12.4.8. Others
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Class
    • 12.7.2. By Route of Administration
    • 12.7.3. By Indication
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Anti-infective Drugs Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Antibacterials
      • 13.2.1.1. B-lactams
      • 13.2.1.2. Quinolones
      • 13.2.1.3. Macrolides
      • 13.2.1.4. Tetracycline
      • 13.2.1.5. Aminoglycoside
      • 13.2.1.6. Others
    • 13.2.2. Antivirals
      • 13.2.2.1. Miscellaneous Antivirals
      • 13.2.2.2. Adamantane Antivirals
      • 13.2.2.3. Antiviral Boosters
      • 13.2.2.4. Others
    • 13.2.3. Antifungals
      • 13.2.3.1. Azoles
      • 13.2.3.2. Echinocandins
      • 13.2.3.3. Polyenes
      • 13.2.3.4. Others
    • 13.2.4. Others
  • 13.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.3.1. Oral
    • 13.3.2. Parenteral
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Indication, 2017-2031
    • 13.4.1. Pneumonia
    • 13.4.2. Sepsis
    • 13.4.3. Tuberculosis
    • 13.4.4. Influenza
    • 13.4.5. HIV Infection
    • 13.4.6. Hepatitis Virus Infection
    • 13.4.7. Respiratory Virus Infection
    • 13.4.8. Others
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. India
    • 13.6.3. Japan
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Class
    • 13.7.2. By Route of Administration
    • 13.7.3. By Indication
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country/Sub-region

14. Latin America Anti-infective Drugs Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Antibacterials
      • 14.2.1.1. B-lactams
      • 14.2.1.2. Quinolones
      • 14.2.1.3. Macrolides
      • 14.2.1.4. Tetracycline
      • 14.2.1.5. Aminoglycoside
      • 14.2.1.6. Others
    • 14.2.2. Antivirals
      • 14.2.2.1. Miscellaneous Antivirals
      • 14.2.2.2. Adamantane Antivirals
      • 14.2.2.3. Antiviral Boosters
      • 14.2.2.4. Others
    • 14.2.3. Antifungals
      • 14.2.3.1. Azoles
      • 14.2.3.2. Echinocandins
      • 14.2.3.3. Polyenes
      • 14.2.3.4. Others
    • 14.2.4. Others
  • 14.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.3.1. Oral
    • 14.3.2. Parenteral
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Indication, 2017-2031
    • 14.4.1. Pneumonia
    • 14.4.2. Sepsis
    • 14.4.3. Tuberculosis
    • 14.4.4. Influenza
    • 14.4.5. HIV Infection
    • 14.4.6. Hepatitis Virus Infection
    • 14.4.7. Respiratory Virus Infection
    • 14.4.8. Others
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Class
    • 14.7.2. By Route of Administration
    • 14.7.3. By Indication
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Anti-infective Drugs Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2017-2031
    • 15.2.1. Antibacterials
      • 15.2.1.1. B-lactams
      • 15.2.1.2. Quinolones
      • 15.2.1.3. Macrolides
      • 15.2.1.4. Tetracycline
      • 15.2.1.5. Aminoglycoside
      • 15.2.1.6. Others
    • 15.2.2. Antivirals
      • 15.2.2.1. Miscellaneous Antivirals
      • 15.2.2.2. Adamantane Antivirals
      • 15.2.2.3. Antiviral Boosters
      • 15.2.2.4. Others
    • 15.2.3. Antifungals
      • 15.2.3.1. Azoles
      • 15.2.3.2. Echinocandins
      • 15.2.3.3. Polyenes
      • 15.2.3.4. Others
    • 15.2.4. Others
  • 15.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.3.1. Oral
    • 15.3.2. Parenteral
    • 15.3.3. Others
  • 15.4. Market Value Forecast, by Indication, 2017-2031
    • 15.4.1. Pneumonia
    • 15.4.2. Sepsis
    • 15.4.3. Tuberculosis
    • 15.4.4. Influenza
    • 15.4.5. HIV Infection
    • 15.4.6. Hepatitis Virus Infection
    • 15.4.7. Respiratory Virus Infection
    • 15.4.8. Others
  • 15.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Class
    • 15.7.2. By Route of Administration
    • 15.7.3. By Indication
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (by Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company, 2022
  • 16.3. Company Profiles
    • 16.3.1. Pfizer Inc.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Gland Pharma Ltd.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Teva Pharmaceutical Industries Ltd.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. F. Hoffmann-La Roche Ltd.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Novartis AG
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. GlaxoSmithKline plc
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Gilead Sciences, Inc.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Merck & Co., Inc.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Abbott
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Astellas Pharma Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Alkem Laboratories
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. AstraZeneca
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview
    • 16.3.13. Eli Lilly and Company
      • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.13.2. Product Portfolio
      • 16.3.13.3. Financial Overview
      • 16.3.13.4. SWOT Analysis
      • 16.3.13.5. Strategic Overview
    • 16.3.14. Johnson & Johnson Services, Inc.
      • 16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.14.2. Product Portfolio
      • 16.3.14.3. Financial Overview
      • 16.3.14.4. SWOT Analysis
      • 16.3.14.5. Strategic Overview
    • 16.3.15. Takeda Pharmaceutical Company Limited
      • 16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.15.2. Product Portfolio
      • 16.3.15.3. Financial Overview
      • 16.3.15.4. SWOT Analysis
      • 16.3.15.5. Strategic Overview
    • 16.3.16. Sanofi
      • 16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.16.2. Product Portfolio
      • 16.3.16.3. Financial Overview
      • 16.3.16.4. SWOT Analysis
      • 16.3.16.5. Strategic Overview